TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 42 to 89 days inclusive on the day of inclusion.~* Born at full term of pregnancy (\>37 weeks).~* Informed consent form signed by the parent(s) or legally authorized representative.~* Able to attend all scheduled visits and to comply with the study procedures.~* Parent or legally authorized representative has access to a telephone.~* Parent or legally authorized representative able to read and write in English or French.~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Personal or immediate family history of congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy.~* Known or suspected systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the trial vaccine(s).~* Chronic illness that could interfere with trial conduct or completion.~* Received blood or blood-derived products since birth.~* Any vaccination preceding the first trial vaccination or planned in the 4 weeks after any trial vaccination (flu vaccine may be given a minimum of 4 weeks prior to the first study vaccination).~* Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis- (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)-conjugate, poliovirus, hepatitis B, or pneumococcal conjugate vaccines.~* Coagulation disorder contraindicating IM vaccination.~* Clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion).~* Developmental delay or neurological disorder.~* Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.~* Documented Hepatitis B surface Antigen (HBsAg) seropositivity in the child or his/her mother.~* History of Hib, hepatitis B, diphtheria, tetanus, pertussis or poliovirus disease.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: EXPERIMENTAL): None
- Group C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Blue Light for Treating Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent prior to any study-mandated procedure~2. Good health as determined by the Investigator according to physical examination~3. Willing and able to comply with study requirements~4. Skin type I-IV according to Fitzpatrick~5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20~6. Comparable clinical symptomatology of both intended treatment Areas~8. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device \[IUD\] or transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study~Exclusion Criteria:~1. Inmates of psychiatric wards, prisons, or other state institutions~2. Investigator or any other team member involved in the conduct of the clinical study~3. Participation in another clinical trial within the last 30 days~4. Pregnant and lactating women~5. Photodermatosis and/or Photosensitivity~6. Porphyria and/or hypersensitivity to porphyrins~7. Congenital or acquired immunodeficiency~8. Patients with any of the following conditions present on the study areas; Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin~9. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome)~10. Current diagnosis of exfoliative or toxic dermatitis.~11. Evidence of superinfection of the intended treatment areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Blue light (Type: EXPERIMENTAL): Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
- Control (Type: NO_INTERVENTION): contralateral untreated control plaque on the same patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 6-month history of migraine~* Migraine attacks typically mild when they begin with 1-4 migraine attacks per month~Exclusion Criteria:~* Heart disease~* High blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Investigator determined diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria with symptomatology from childhood to adulthood, symptoms present before age seven years and continue to meet full DSM-IV criteria at time of assessment~* Diagnosis confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) at Baseline and Adult ADHD Investigator Symptom Rating Scale (AISRS) score of 24 or greater as determined by the Investigator at Baseline~* Global Assessment of Functioning (GAF) Scale score of 41 to 60, inclusive, at Baseline~* Minimum weight of 100 lbs (45.4 kg) at Screening~* Negative urine drug test at the Screening and Baseline Visits when tested for drugs of abuse~Exclusion Criteria:~* Known to be non-responders to methylphenidate or other stimulants for the treatment of ADHD~* History of allergy, sensitivity or contraindication to methylphenidate or components of methylphenidate HCl extended-release tablets~* Coexisting medical condition or taking concomitant medication that would interfere with safe administration of methylphenidate in the Investigator's opinion~* Known structural cardiac abnormality~* Diagnosis of or family history of Tourette's syndrome, or motor or verbal tics~* History of seizures or a seizure disorder other than febrile seizures in childhood~* Glaucoma~* Uncontrolled hyperthyroidism or hypothyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented clinical diagnosis of Major Depressive Disorder.~* Be able to understand and comply with the requirements of the study.~* Able to understand and provide written informed consent~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Current or past diagnosis of stroke or transient ischemic attack (TIA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination.~* A minimum of 20 permanent gradable teeth~* Moderate gingivitis present at the screening visit in the opinion of the investigator~* A total of 20 bleeding sites or greater at baseline visit~* Positive response to bleeding on brushing present at the screening visit~Exclusion Criteria:~* Pregnant or breast feeding women~* Tobacco chewers~* Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participant or undermines the data validity.~* Recent history (within the last year) of alcohol or other substance abuse~* Participants requiring prophylactic antibiotic treatment prior to dental therapy~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients~* Have current active caries or any medical conditions which may directly influence gingival bleeding~* Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations~* Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index~* Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit~* An employee of the sponsor or the study site or members or their immediate family.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Experimental Dentifrice (Type: EXPERIMENTAL): Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
- Reference Dentifrice (Type: ACTIVE_COMPARATOR): Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with airflow limitation indicated by a post-bronchodilator FEV1 \<80% of the predicted normal value and a post-bronchodilator FEV1/FVC\<0.7~* Current or ex-smokers who have a smoking history of at least 10 pack years.~* Able and willing to give written informed consent~* Hyperinflated patients with RVol\>135% predicted~Exclusion Criteria:~* Patients on LABA or LAMA treatment at Visit 1.~* History of one COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization 3 months prior to Visit 2.~* More than one COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization within 6 months prior to Visit 2.~* Patients who have clinically significant cardiovascular abnormalities, which could interfere with the assessment of the study treatment (such as but not limited to cardiac arrhythmias, heart failure with left ventricular ejection fraction \<40% as determined by MRI scan, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, history of myocardial infarction 6 months prior to Visit 2)~* Patients with a known history or current atrial fibrillation to be confirmed by ECG.~* Patients with pacemaker, bypass or stent.~* Patients whose QTcF measured at Visit 3 is \>450 ms for males and \>470 ms for females~Additional study-specific inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment sequence 1 (Type: EXPERIMENTAL): QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
- Treatment sequence 2 (Type: EXPERIMENTAL): Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older,~2. injected heroin, cocaine, or other drugs in the past 90 days.~3. test HCV Ab and RNA positive~4. provide written consent (including consent for researchers to examine their hepatitis C medical records)~Exclusion Criteria:~Persons already in care for hepatitis C, defined as having had at least 2 visits with a hepatitis treatment provider within the past 6 months, will be excluded.~People with decompensated cirrhosis will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accessible Care (Type: EXPERIMENTAL): Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
- Usual Care (Type: ACTIVE_COMPARATOR): Usual care represents the current process after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 18-75 year-old~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2~3. Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CP-CML) within 6 months of diagnosis~4. Adequate organ function~Exclusion Criteria:~1. received TKIs drug treatment before enrollment~2. Central nervous system leukemia~3. Previous anti-CML therapy over two weeks (hydroxyurea, except anagrelide) or surgery (including hematopoietic stem cell transplantation)~4. Cardiac dysfunction~5. Previous splenectomy~6. History of congenital or acquired bleeding disorders unrelated to CML~7. Previous malignancy except CML~8. Acute or chronic liver or severe kidney disease unrelated to CML~9. Pregnant, breastfeeding, child bearing potential but failed to take effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Flumatinib mesylate tablets (Type: EXPERIMENTAL): Flumatinib mesylate tablets 600mg qd for 12 months
- Imatinib mesylate tablets (Type: ACTIVE_COMPARATOR): Imatinib mesylate tablets 400mg qd for 12months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20 to 75~* Performance status 0 , 1, or 2 (ECOG)~* Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3~* Hepatic AST and ALT ≤ 2 times upper limit of normal(ULN) Total bilirubin ≤ 1.5 times ULN~* Renal BUN ≤1.5 times ULN Creatinine ≤ 1.5 times ULN~Exclusion Criteria:~* Prior anticancer treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): UFT (uracil, tegafur)
- 2 (Type: OTHER): Surgery alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Value of CT Fractional Flow Reserve

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
1. Inclusion Criteria:~2. Capable of giving informed consent.~3. Able to cooperate with the technician performing the procedure.~4. Patient must have Body Mass Index (BMI) \<= 50.~5. Patients must have non-ST Elevation Myocardial Infarction (STEMI) Electrocardiogram (EKG) without acute changes.~6. Patients must present to Research Institution with medically necessary appointment for CCTA for the purpose of evaluation of coronary stenosis for the provisional diagnoses of chest pain or angina or angina equivalent.~7. Patients must be able to take nitroglycerin and beta blockers. -~8. Patients must be 18 years of age or older.~Exclusion Criteria:~1. Patients must not have a history of coronary stenting or coronary artery bypass graft.~2. Patients must not have severe or end stage renal disease as diagnosed as estimated glomerular filtration rate (eGFR)\<50.~3. Patients must not have a BMI\>50.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: HeartFlow CT-FFR Arm (Type: None): All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Subjects diagnosed with type 2 diabetes mellitus~* HbA1c 7.0-11.0% (both inclusive) (53-97 mmol/mol) by central laboratory analysis~* Body mass index greater than or equal to 20 kg/m\^2~* Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes~* Stable daily dose(s) including any of the following antidiabetic drug(s)/regimens within 90 days prior to the day of screening: a) Biguanides (metformin greater than or equal to 1500 mg or maximum tolerated dose documented in the subject medical record), b) Other OAD(s) allowed: sulphonylurea, glinides, pioglitazone, and DPP4-inhibitors (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subjects medical record)~Exclusion Criteria:~* Screening calcitonin greater than or equal to 50 ng/L~* Renal impairment estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/1.73 m2 as per CKD-EPI value to be defined as listed in the classification CKD-EPI using IDMS for serum creatinine measurement on the day of screening~* Impaired liver function, defined as ALAT or ASAT greater than or equal to 2.5 times upper limit of normal~* Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma~* History of pancreatitis (acute or chronic)~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening~* Anticipated initiation or change in concomitant medications for more than 14 consecutive days or on a frequent basis known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide QD + OAD(s) (Type: EXPERIMENTAL): None
- insulin glargine QD + OAD(s) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete